Sex Differences in Active Pulmonary Tuberculosis Outcomes in Mali, West Africa

• Published in: The American journal of tropical medicine and hygiene 2022-08, Vol.107 (2), p.433-440
• Main Authors: Dabitao, Djeneba, Somboro, Amadou, Sanogo, Ibrahim, Diarra, Bassirou, Achenbach, Chad J, Holl, Jane L, Baya, Bocar, Sanogo, Moumine, Wague, Mamadou, Coulibaly, Nadie, Kone, Mahamadou, Drame, Hawa Baye, Tolofoudie, Mohamed, Kone, Bourahima, Diarra, Ayouba, Coulibaly, Mamadou D, Saliba-Shaw, Kathryn, Toloba, Yacouba, Diakite, Mahamadou, Doumbia, Seydou, Klein, Sabra L, Bishai, William R, Diallo, Souleymane, Murphy, Robert L
• Format: Article
• Language: English
• Subjects: Gender differences; Males; Tuberculosis
• ISSN: 0002-9637; 1476-1645
• DOI: 10.4269/ajtmh.21-1141

Men and women often respond differently to infectious diseases and their treatments. Tuberculosis (TB) is a life-threatening communicable disease that affects more men than women globally. Whether male sex is an independent risk factor for unfavorable TB outcomes, however, has not been rigorously investigated in an African context, where individuals are likely exposed to different microbial and environmental factors. We analyzed data collected from a cohort study in Mali by focusing on newly diagnosed active pulmonary TB individuals who were treatment naive. We gathered baseline demographic, clinical, and microbiologic characteristics before treatment initiation and also at three time points during treatment. More males than females were affected with TB, as evidenced by a male-to-female ratio of 2.4:1. In addition, at baseline, males had a significantly higher bacterial count and shorter time to culture positivity as compared with females. Male sex was associated with lower smear negativity rate after 2 months of treatment also known as the intensive phase of treatment, but not at later time points. There was no relationship between patients' sex and mortality from any cause during treatment. This study suggests that sex-based differences in TB outcomes exist, with sex-specific effects on disease outcomes being more pronounced before treatment initiation and during the intensive phase of treatment rather than at later phases of treatment.